This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, H. Articles by Maihle, N. J. Search for Related Content PubMed PubMed Citation Articles by Lee, H. Articles by Maihle, N. J.

A Naturally Occurring Secreted Human ErbB3 Receptor Isoform Inhibits Heregulin-stimulated Activation of ErbB2, ErbB3, and ErbB4¹

Tumor Biology Program, Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905 [H. L., N. J. M.], and Department of Molecular Oncology, Genentech, Inc., South San Francisco, California 94080 [R. W. A., M. X. S.]

A variety of receptor-mediated signaling pathways are controlled by both positive and negative extracellular regulators. In this study, we demonstrate that a naturally occurring secreted form of the human ErbB3 receptor, p85-soluble ErbB3 (sErbB3), is a potent negative regulator of heregulin (HRG)-stimulated ErbB2, ErbB3, and ErbB4 activation. We show that p85-sErbB3 binds to HRG with an affinity comparable to that of full-length ErbB3 and competitively inhibits high affinity HRG binding to ErbB2/ErbB3 heterodimers on the cell surface of breast carcinoma cells with an IC₅₀ of 0.5 nM. p85-sErbB3 inhibits HRG-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in breast carcinoma-derived cell lines and can also block HRG-stimulated activation of mitogen-activated protein kinase, Akt, and association of ErbB3 with the phosphatidylinositol 3'-kinase p85 regulatory subunit. Cell growth assays show that exogenous addition of a 100-fold molar excess of p85-sErbB3 inhibits HRG-stimulated cell growth by as much as 90%. Whereas several potential mechanisms of p85-sErbB3 inhibition of ErbB receptor activation exist, our results suggest that at least one means of inhibition is competition for HRG binding. The IC₅₀ for both p85-sErbB3- and 2C4 (a monoclonal antibody specific for ErbB2)-mediated inhibition of HRG binding is approximately 0.5 nM, although the mechanism of inhibition by these two proteins is distinct. Together these results suggest that p85-sErbB3 is a naturally occurring negative regulator of HRG-stimulated signal transduction that may have important therapeutic applications in human malignancies associated with HRG-mediated cell growth such as breast and prostate cancer.

This article has been cited by other articles:

				M. Narayan, J. A. Wilken, L. N. Harris, A. T. Baron, K. D. Kimbler, and N. J. Maihle Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells Cancer Res., March 15, 2009; 69(6): 2191 - 2194. [Abstract] [Full Text] [PDF]

				S.-H. Lin, Y.-C. Lee, M. B. Choueiri, S. Wen, P. Mathew, X. Ye, K.-A. Do, N. M. Navone, J. Kim, S.-M. Tu, et al. Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer Clin. Cancer Res., June 15, 2008; 14(12): 3729 - 3736. [Abstract] [Full Text] [PDF]

				J. L. Reiter, N. J. Maihle, and G. M. Clinton Therapeutic potential of epidermal growth factor receptor-related protein. Mol. Cancer Ther., November 1, 2006; 5(11): 2954 - 2954. [Full Text] [PDF]

				K.-L. Schaefer, K. Brachwitz, D. H. Wai, Y. Braun, R. Diallo, E. Korsching, M. Eisenacher, R. Voss, F. van Valen, C. Baer, et al. Expression Profiling of t(12;22) Positive Clear Cell Sarcoma of Soft Tissue Cell Lines Reveals Characteristic Up-Regulation of Potential New Marker Genes Including ERBB3 Cancer Res., May 15, 2004; 64(10): 3395 - 3405. [Abstract] [Full Text] [PDF]

				Q. A. Justman and G. M. Clinton Herstatin, an Autoinhibitor of the Human Epidermal Growth Factor Receptor 2 Tyrosine Kinase, Modulates Epidermal Growth Factor Signaling Pathways Resulting in Growth Arrest J. Biol. Chem., May 31, 2002; 277(23): 20618 - 20624. [Abstract] [Full Text] [PDF]